Without the need for the usual response from our friend Shinchu and her commentary which ultimate leads to her conclusion that ILI should be valued at $0.50 or less; it is very disappointing to see the freefall after Q2 earnings.
IMHO the conference call was upbeat and positive. Any intelligent ideas why ILI is getting hammered? Has the short position significantly increased?
I wouldnt underestimate the alliance between ILI and Alticor. In the conference call, Alticor was referred to numerous times. This is, in a sense, a small Alticor that is publicly traded. The initial investment Alticor made in 2003 has risen on any given day six to eight fold. More importantly, ILI is the integral part of the personalized medicine for Alticor. Since the international part of Alticor represents a majority of the revenues, i wouldnt judge ILI's sales until those areas are launched.